Market Outlook

According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being underutilized, migraine prophylaxis is a core treatment approach in reducing migraine frequency, severity, and duration. Prescription options include a diverse mix of on- and off-label oral drugs, newly launched anti-CGRP MAbs (i.e., Amgen / Novartis’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality), and Allergan’s Botox, which the FDA approved specifically for chronic migraine prevention. Prophylaxis is both individualized and dynamic, as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as new preventives establish themselves in the market.

Questions Answered

  • What patient shares do key therapies and brands garner by line of therapy in migraine patients initiating prophylaxis? What are the quarterly trends in prescribing recently treated and prophylactically naive migraine patients?
  • How has Aimovig been integrated into the treatment algorithm, and what claims share did it capture by the end of Q4 2018?
  • What percentage of prophylactically naive migraine patients began drug therapy within our two-year prescription-tracking period? What percentage of patients progress to later lines of therapy, and how quickly do they progress?
  • What percentage of migraine patients are treated with monotherapy vs. combination therapy? What are the most frequently used combinations?
  • What are the product-level compliance and persistency rates among prophylactically treated patients?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Aimovig, Ajovy, Emgality, Botox, topiramate IR, Trokendi XR, Qudexy XR, topiramate XR, propranolol, amitriptyline, verapamil, others

Key analysis provided:

  • Brand / therapy use across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis)
    • Treatment Algorithms CDA: Migraine Prophylaxis US May 2019

Author(s): Audreza Das, P.G. Dip

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

Related Reports

Migraine | Landscape & Forecast | Disease Landscape & Forecast

The migraine therapy market comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. We anticipate the launch of several new brands, includin...

View Details

Migraine | Emerging Therapies | Aimovig-Migraine Prevention Wave 3 (US)

Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth...

View Details

Migraine | Emerging Therapies | Ajovy and Emgality - Migraine (Wave 2) US

Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in...

View Details

Migraine | Emerging Therapies | Ajovy and Emgality - Migraine (Wave 3) US

Coming Soon – November 2019 Market Outlook The migraine prophylax...

View Details